SCHEMBL4243583

SCHEMBL4243583

O=C(NCc1ccc(F)cc1F)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.47
MAOB P27338 1/20 0.46
RIPK1 Q13546 3/20 0.44
PDE10A Q9Y233 1/20 0.43
GSK3B P49841 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
EPHX2 P34913 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
BDKRB1 P46663 4/20 0.42
VNN1 O95497 1/20 0.41
KCNA5 P22460 1/20 0.41
MAPK8 P45983 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17882323 0.81 RIPK1 (0.69) P2RX7MAOBRIPK1PDE10AEPHX2
SCHEMBL29912736 0.81 RIPK1 (0.69) P2RX7MAOBRIPK1PDE10AEPHX2
SCHEMBL3568253 0.81 P2RX7 (0.53) P2RX7MAOBGSK3BMEN1KMT2A
SCHEMBL9160975 0.80 RIPK1 (0.52) P2RX7MAOBRIPK1MEN1KMT2A
SCHEMBL5315312 0.79 P2RX7 (0.52) P2RX7MAOBRIPK1PDE10AGSK3B
SCHEMBL626266 0.79 P2RX7 (0.49) P2RX7MAOBPDE10AGSK3BMEN1
SCHEMBL5317199 0.79 P2RX7 (0.49) P2RX7MAOBPDE10AGSK3BMEN1
SCHEMBL23482150 0.77 P2RX7 (0.56) P2RX7MAOBRIPK1PDE10AMEN1
SCHEMBL30259905 0.77 P2RX7 (0.56) P2RX7MAOBRIPK1PDE10AMEN1
SCHEMBL23981793 0.77 P2RX7 (0.53) P2RX7MAOBGSK3BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-05-27 US disclosed
US-6686395-B2 THERAPY OF A CARDIAC ARRYTHMIA WHICH CAN BE ELIMINATED BY ACTION POTENTIAL PROLONGATION; POTASSIUM CHANNEL MODULATOR AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-02-03 US disclosed
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6531495-B1 Potassium channel AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, KCNH1 P2RX7 468/4885MAOB 683/4885RIPK1 4487/4885
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E P2RX7 426/4885MAOB 654/4885RIPK1 4517/4885
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, CACNA1E P2RX7 444/4885MAOB 702/4885RIPK1 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.